Playlist


The State Circus of Turkmenistan invites residents and visitors of Ashgabat to a grand performance scheduled for May 3rd at 6:00 PM. This upcoming showcase is designed to highlight the artistic diversity and technical prowess of the national circus school. The event promises an evening of high-energy entertainment, bringing together seasoned professionals and emerging talents under the big top.
The program features a wide array of acts, ranging from breathtaking aerial acrobatics to impressive displays involving trained animals. Highlighting the evening will be the world-renowned "Galkynysh" national equestrian group, famous for their daring stunts and traditional horsemanship. They will be joined by the "Turkmen Jigitleri" and the youthful "Gundogar Ýyldyzlary" troupe, ensuring a dynamic mix of traditional and contemporary circus genres.
In addition to the physical feats of the performers, the show will include comedic interludes and theatrical skits designed to engage the entire family. The organizers have integrated modern sound and lighting systems to enhance the visual impact of each act, creating a fully immersive cultural experience. This performance serves as a testament to the ongoing development and international prestige of Turkmenistan's circus arts.
To facilitate easier access for the public, tickets are available for purchase online through the circus's official digital platform. Detailed information regarding seating, pricing, and event logistics can also be obtained via the dedicated customer service phone lines. This performance is expected to be a highlight of the spring cultural calendar, offering a unique blend of heritage and excitement.
Also read


Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds
Today in 02:02Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.
Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.